R
Robert C. Moellering
Researcher at Beth Israel Deaconess Medical Center
Publications - 297
Citations - 24622
Robert C. Moellering is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Antibiotics & Vancomycin. The author has an hindex of 83, co-authored 297 publications receiving 23781 citations. Previous affiliations of Robert C. Moellering include Harvard University & Deaconess Hospital.
Papers
More filters
Book
The Sanford guide to antimicrobial therapy
David N. Gilbert,Robert C. Moellering,George M. Eliopoulos,Henry F. Chambers,Michael S. Saag +4 more
TL;DR: The sanford guide to antimicrobial therapy – trusted infectious diseaseRecommendations for antimicrobial usage and best practices for using antimicrobial agents in clinical practice are provided.
Journal ArticleDOI
Antimicrobial-drug resistance.
TL;DR: Since their discovery, antimicrobial drugs have proved remarkably effective for the control of bacterial infections, however, it was soon evident that bacterial pathogens were unlikely to surrender unconditionally, because some pathogens rapidly became resistant to many of the first effective drugs.
Journal ArticleDOI
Linezolid resistance in a clinical isolate of Staphylococcus aureus
Sotirios Tsiodras,Sotirios Tsiodras,Howard S. Gold,Howard S. Gold,George Sakoulas,George Sakoulas,George M. Eliopoulos,George M. Eliopoulos,Christine Wennersten,Lata Venkataraman,Robert C. Moellering,Robert C. Moellering,Mary Jane Ferraro +12 more
TL;DR: An MRSA isolate resistant to linezolid is characterised that was recovered from a patient treated with this agent for dialysis-associated peritonitis.
Journal ArticleDOI
Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
George Sakoulas,Pamela A. Moise-Broder,Jerome J. Schentag,Alan Forrest,Robert C. Moellering,George M. Eliopoulos +5 more
TL;DR: It is concluded that a significant risk for vancomycin treatment failure in MRSA bacteremia begins to emerge with increasing vancomYcin MICs well within the susceptible range.
Journal ArticleDOI
Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists
Michael J. Rybak,Ben M. Lomaestro,John C. Rotschafer,Robert C. Moellering,Willam A. Craig,Marianne Billeter,Joseph R. Dalovisio,Donald P. Levine +7 more
TL;DR: A literature review of existing evidence regarding vancomycin dosing and monitoring of serum concentrations, in addition to patient outcomes combined with expert opinion regarding the drug's pharmacokinetic, pharmacodynamic, and safety record, resulted in new recommendations for targeting and adjustment of vancomYcin therapy.